The two cancer drugs can potentially slow or reverse. Alzheimer’s diseasenew research suggests.
Researchers at the University of California, San Francisco (UCSF) have investigated how dementia, common in certain brain cells, alters gene expression (genes on or off), according to a press release from the university.
Then they saw the existing ones FDA approved drugs It could negate or reverse those changes.
The risk of Alzheimer’s disease can be increased in certain sleep patterns, experts warn
In the analysis of millions of electronic medical records Adults over 65 years oldresearchers identified two drugs that appear to reduce the likelihood of Alzheimer’s disease in patients who took them.
Drugs – Retrozone and Irinotecan are both approved for the treatment of cancer. Letrozole is a breast cancer drug, irinotecan treats the colon, lung cancer.
When scientists tested both drug combinations in mice, they focused on the reversal of gene expression changes initiated by Alzheimer’s disease.
They also found a reduction in protein clumps in tau With the brain – Important markers of Alzheimer’s disease – Improvement of learning and memory.
“Alzheimer’s disease has been accompanied by complex brain changes that make it difficult to study and treat, but our calculators have opened up the possibility of addressing complexity directly,” said Dr. Marina Sirota, interim director of UCSF Bakar Computing Health Science Institute and interim director of pediatrics for the press release.
Eating these common foods can reduce the risk of Alzheimer’s disease, experts say
“We are excited that our calculation approach has led us to a potential combination therapy for Alzheimer’s disease based on existing FDA-approved drugs.”
The results of the study, partially funded by the National Institutes of Health (NIH) and the National Science Foundation, were published in the Journal Cell on July 21.
Although the results of this study were promising, the researchers acknowledged some limitations, including the fact that a database was constructed that was used to identify possible drugs. Cancer cellsnot brain cells.
They also noted that animal models were used.
“Although it is necessary, validation of animal models may not completely replicate human biology,” the researchers write.
Men face risk of double dementia when genetic mutations are hidden
Additionally, male mice responded better than females, and there were significant gender differences in their response to drugs.
“As a hormone modulator, letrozole may contribute to this gender difference,” the team noted. “However, the analysis is inconclusive because of the small number of male letrozole users.”
Electronic medical records can also provide restrictions as data tends to be sparse and not collected. Specific research Keep in mind. ”
According to the Alzheimer’s Association, more than 7 million people in the United States currently live with Alzheimer’s disease.
This number is expected to approach 13 million by 2050.
Currently, there are only two FDA-approved disease modifiers for the treatment of Alzheimer’s disease.
Leqembi and Donanemab (Kisunla) are both monoclonal antibodies administered via IV injection.
They work by reducing the accumulation of amyloid plaque in the brain, but they are only effective in people with early stage Alzheimer’s disease and have some serious potential Side effectsAccording to experts.
(Other Alzheimer’s medications can help with symptoms, but do not treat the underlying disease.)
Click here to sign up for our health newsletter
“Alzheimer’s disease is likely the result of numerous changes in many genes and proteins that are confusing together Brain health“Yadon Hwang, Yadong Hwang, Yadong Hwang, Yadong Hwang, Yadong Hwang and Yadong Hwang, professors of neurology and pathology at UCSF, said in the release.
“This makes it extremely difficult for drug development. It traditionally produces one drug for a single gene or protein that promotes disease.”
Looking ahead, researchers plan to launch clinical trials to investigate the impact of concomitant drugs on human patients due to Alzheimer’s disease.
“If a completely independent data source, such as single-cell expression data and clinical records, is guided by the same pathway and the same drug to resolve Alzheimer’s disease Genetic modeland then maybe we’re working on something,” Shirota said in the release.
Visit us for more health articles www.foxnews.com/health
“We hope this will quickly translate into a real solution for millions of Alzheimer’s patients.”
